Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Overview of attention for article published in Journal of Translational Medicine, June 2022

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 906 followers.

New article: Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer https://t.co/xQCuRMc4lY #lungcancer #oncology https://t.co/XZ4Pc0L5Dd

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.